New drug duo aims to outsmart resistant lung cancer
Disease control
Recruiting now
This study is testing whether adding a drug called savolitinib to a standard drug (osimertinib) can help control advanced lung cancer that has developed resistance to treatment. It is for adults whose cancer has specific genetic changes (EGFR mutation and low-level MET amplificat…
Phase: PHASE2 • Sponsor: Qingdao Central Hospital • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC